Good Manufacturing Practices (GMP) and Quality Assurance (QA): Complete Guide with QA vs QC, ALCOA+, CAPA & ICH Q9

Table of Contents

• Introduction to GMP and Quality Assurance
• The Relationship between QA, GMP, and QC
• Global Regulatory Standards (FDA, EMA, TGA, Health Canada)
• Documentation and Data Integrity (ALCOA+)
• Personnel Hygiene
• Training
• Premises, Equipment, and Utilities
• Validation and Qualification
• Quality Risk Management (ICH Q9)
• Handling Deviations and CAPA
• Conclusion
• References

Ready Made Presentation Link

Introduction to GMP and Quality Assurance

• Quality Assurance (QA) is a broad and comprehensive concept that includes all factors which individually or collectively influence the quality of a product, ensuring that the final product meets the required standards
• Good Manufacturing Practice (GMP), also known as Current Good Manufacturing Practice (cGMP), is a key component of QA
• GMP refers to a structured set of guidelines designed to control every aspect of pharmaceutical production
• These guidelines are enforced by regulatory authorities to ensure that drug products are:
• Fit for their intended use
• In compliance with the requirements of marketing authorization
• Safe and do not pose any harm to the end user
• The first draft of GMP guidelines was prepared by the World Health Organization (WHO) in 1967, developed by a group of consultants at the request of the Twentieth World Health Assembly
• GMP covers multiple critical areas of pharmaceutical manufacturing, including:
• Hygiene
• Validation
• Self-inspection
• Personnel
• Premises
• Equipment
• Materials
• Documentation

The Relationship between QA, GMP, and QC

• Quality Assurance (QA), Good Manufacturing Practice (GMP), and Quality Control (QC) work collectively to maintain the quality of pharmaceutical products in accordance with regulatory requirements
• Quality management in the pharmaceutical industry is the responsibility of all personnel, not just specific departments
• The fundamental elements of quality management include:
• An appropriate infrastructure or quality system
• Organizational structure
• Established procedures and processes
• Availability of resources
• Systematic actions necessary to ensure that products meet defined quality requirements
• The totality of all these actions is referred to as Quality Assurance (QA)

GMP and QA

• QA plays a central role in defining and implementing standards across pharmaceutical operations
• QA is responsible for establishing:
• Standards
• Procedures
• Protocols
• Specifications for manufacturing, testing, and quality control activities
• Quality Control (QC) is responsible for verifying that products comply with the specifications and standards set by QA
• QA provides guidance, instructions, and protocols to all departments within the pharmaceutical industry
• Continuous feedback and information exchange between departments helps to:
• Identify areas for improvement
• Detect quality issues
• Evaluate process effectiveness

Importance of QA and QC Personnel for GMP Implementation

• Trained and Qualified Personnel
• QA, QC, and production personnel must be properly trained and educated in:
• GMP principles
• Quality control techniques
• Documentation practices
• Training should include:
• Standard Operating Procedures (SOPs)
• Risk assessment
• Change control
• Validation protocols
• Ongoing training programs ensure consistent product quality
• Skilled and qualified personnel are essential for maintaining GMP standards

Implementation of Documented Procedures and Standard Operating Practices

• All QA, QC, and production activities must be properly documented
• Documentation should be:
• Regularly reviewed
• Accurately reproduced
• Effectively communicated
• Proper documentation minimizes errors, deviations, and inconsistencies

Following Testing and Sampling Protocols

• QC personnel must conduct sampling and testing according to:
• Specifications
• Protocols established by QA
• These protocols should be based on:
• Recognized standards
• Validated analytical methods
• This ensures accurate, reliable, and reproducible results

Risk Assessment and Management

• Both QA and QC must incorporate risk assessment strategies
• These strategies help to:
• Identify potential risks
• Minimize risks throughout the manufacturing and testing processes

Ensuring Product Safety and Efficacy

• QA and QC together ensure:
• Product safety
• Potency
• Efficacy
• Through testing, inspection, and documentation, they confirm that products meet quality standards
• This protects patient health and prevents harmful or adverse effects

Building Customer Trust and Satisfaction

• Consistency in product quality is maintained through QA and QC systems
• This builds:
• Customer confidence
• Product reliability
• Brand trust and loyalty

Minimizing Risks and Costly Recalls

• Effective QA and QC systems help reduce:
• Product defects
• Manufacturing errors
• Product recalls
• Preventive measures, testing, and inspections help detect issues before they escalate

Promoting Continuous Improvement and Innovation

• QA and QC activities help identify:
• Areas for improvement
• Opportunities to optimize manufacturing processes
• Ways to enhance product quality
• Strong interdepartmental communication fosters:
• Innovation
• Continuous improvement
• Competitiveness in the evolving pharmaceutical industry

Global Regulatory Standards (FDA, EMA, TGA, Health Canada)

Different countries have specific regulatory bodies responsible for enforcing GMP regulations to ensure the safety, quality, and efficacy of pharmaceutical and medical products

FDA (Food and Drug Administration)

• The Food and Drug Administration focuses on ensuring the safety and quality of:
• Pharmaceuticals
• Dietary supplements
• Certain food products
• The FDA regulates:
• Documentation of manufacturing processes
• Rigorous quality control and testing procedures
• Validation of equipment and processes
• Adherence to hygiene and cleanliness standards

European Medicines Agency (EMA)

• The European Medicines Agency enforces European Union GMP practices
• These regulations are based on:
• A comprehensive quality management system
• Risk-based approaches to pharmaceutical quality
• Validation of computerized systems
• Minimization of cross-contamination during manufacturing

Therapeutic Goods Administration (TGA)

• The Therapeutic Goods Administration is the regulatory authority of the Australian government for medical products, including biologics
• TGA regulates GMP compliance for:
• Pharmaceuticals
• Medical devices
• Therapeutic goods
• Key aspects of TGA GMP include:
• Risk-based manufacturing controls
• Compliance with international standards
• Emphasis on process validation and stability testing
• Continuous improvement through post-market monitoring

Health Canada

• Health Canada is responsible for regulating drugs and medical devices in Canada
• Its regulations are largely based on FDA standards and are considered among the strictest globally
• Health Canada ensures:
• Stringent product testing
• Maintenance of detailed records
• Strong emphasis on quality assurance
• Regular inspections of manufacturing facilities

The 10 Golden Rules of GMP

• The Golden Rules of GMP cover the entire process from initial industrial development to regular internal and external quality checks, ensuring compliance with regulatory standards to maintain product quality
• Get the facility design right from the start: A well-designed facility helps prevent contamination, mix-ups, and errors
• Validate processes: Provide documented evidence that processes and procedures consistently produce the same results
• Write good procedures and follow them: Proper GMP documentation ensures procedures are clear and easy to follow
• Identify roles and responsibilities: Establish organograms, job descriptions, and defined responsibilities to avoid confusion and ensure clear reporting structures
• Keep good records: Follow good documentation practices to maintain traceability and accountability of all processes
• Train and develop staff: Regular training improves performance, reduces defects, and increases job satisfaction
• Practice good hygiene: Maintain personnel hygiene and facility cleanliness to ensure product safety, quality, and efficacy
• Maintain facilities and equipment: Regular maintenance ensures consistent performance and reduces contamination risks
• Build quality into the entire product lifecycle: Incorporating quality at every stage helps prevent future problems
• Perform regular audits: Conduct internal GMP audits at regular intervals to identify gaps and improve compliance levels

Documentation and Data Integrity (ALCOA+)

• Documentation is a systematic process that involves preparing, reviewing, approving, issuing, and storing records to ensure compliance with Good Manufacturing Practice (GMP) and Good Documentation Practice (GDP)
• It serves as physical evidence and acts as the backbone of manufacturing and quality control by ensuring product consistency, traceability of errors, and documented proof of corrective actions
• The purposes of documentation include:
• Defining specifications and procedures for all materials and methods of manufacture and control
• Ensuring that all personnel involved in manufacturing clearly understand what to do and when to do it
• Providing authorized personnel with complete information to decide whether a batch of medicine can be released for sale
• Ensuring documented evidence, traceability, and availability of records for audit trails and investigations
• Supporting validation processes, reviews, and statistical analysis through reliable data availability
• Documents must have clear and unambiguous content, with properly defined title, nature, and purpose

General Principles of Documentation

• Documents should be properly controlled by regular review and updates, and while superseded documents must be retained for a defined period, their unintended use must be strictly prevented
• Data entry must be clear, legible, and indelible, with all entries recorded on the actual date of entry and signed or initialed by the responsible person
• Any alteration in data must be signed and dated, carried out in a way that preserves the original information, and must include a clearly stated reason for the change
• Complete records of each manufacturing batch must be maintained from initial stages to final product release, and these records should be retained for at least one year after the expiry date of the finished product

Types of Documentation

Documentation in pharmaceutical systems includes various essential records such as labels for different stages of production, specifications, master formula documents, batch processing records, batch packaging records, standard operating procedures (SOPs), site master files, and distribution records

Data Integrity

• Data integrity refers to maintaining the accuracy, completeness, and consistency of data throughout its entire lifecycle
• It ensures the quality, safety, and efficacy of pharmaceutical products and supports accurate evaluation of product performance
• Strong data integrity practices help prevent adverse drug reactions and ensure that only authentic and reliable information is used in decision-making and regulatory processes
• The principle of data integrity is based on ALCOA, which has been expanded to ALCOA+

ALCOA+ Principles

• Attributable: Data must be traceable to the individual who generated it, including clear identification of who recorded the data and when it was recorded
• Legible: All recorded data must be clear, readable, and permanent, avoiding informal language or abbreviations that could create confusion over time
• Contemporaneous: Data must be recorded at the time the activity occurs, including accurate date and time entries for both original records and any modifications, as delays can compromise data quality
• Original: Original data represents the first recorded information and must be preserved to verify authenticity and validate any copies
• Accurate: Data must be correct, error-free, and within defined limits, often verified through checks such as range validation and outlier detection
• Complete: All data related to an activity must be recorded, including repeat analyses, errors, corrections, and deviations, ensuring full transparency and preventing data manipulation
• Consistent: Data should follow a logical chronological order and standardized formats, ensuring clarity and reliability, which is often verified through regular audits
• Enduring: Data must be recorded on durable and permanent media and preserved for the required retention period to ensure long-term accessibility and reliability
• Available: Data should be easily accessible for review, verification, and regulatory inspection, with proper backup systems in place to support audits and compliance

Personnel hygiene

• Personnel hygiene must be maintained at every stage of pharmaceutical processing to ensure product safety and quality
• All personnel should undergo health assessments both prior to employment and during employment, including eye examinations, general health checkups, and routine sanitization practices
• A high standard of personal hygiene must be consistently followed by all individuals involved in the manufacturing process
• Hands must be thoroughly washed and sanitized before entering and after leaving production or sensitive areas to prevent contamination
• Personnel should wear clean protective clothing, including appropriate body coverings and hair covers, according to their specific duties
• Direct contact with products or any surfaces that may come into contact with products must be avoided; protective gloves should be worn when handling open products
• Hands should be well maintained, with short, clean nails, and must be free from lesions, wounds, cuts, boils, or any potential sources of infection
• The use of jewelry such as rings and earrings, as well as makeup, is prohibited to minimize contamination risks
• All personnel must strictly follow Standard Operating Procedures (SOPs) to ensure compliance with hygiene and safety standards

Training

• Training must be provided according to a written and approved program for all personnel whose responsibilities involve production areas, quality control laboratories, or any other activities that may impact product quality, including technical, maintenance, and cleaning staff
• All personnel should receive basic training related to GMP and Quality Assurance (QA) concepts to ensure a clear understanding of quality standards and responsibilities
• Newly recruited personnel must be given training specifically tailored to the duties and responsibilities assigned to them before they begin their work
• Continuous training programs should be conducted to maintain and improve practical effectiveness, ensuring personnel remain updated with current practices and standards
• Proper training records must be maintained as documented evidence of training activities and compliance
• Personnel working in areas where there is a risk of contamination must receive specialized training to handle such risks effectively and maintain product safety

Premises, Equipment, and Utilities

Premises

• Premises refer to all buildings where pharmaceutical manufacturing activities take place and must be properly located, designed, constructed, adapted, and maintained to suit the intended operations
• The layout and design of premises should prevent adverse effects on product quality by minimizing risks such as cross-contamination and errors, while also allowing effective cleaning and maintenance
• Proper separation of material flow and personnel flow must be ensured to reduce contamination risks
• Premises are divided into specific functional areas to maintain efficiency and compliance

Ancillary Areas

• Ancillary areas, often referred to as black areas, include rest and refreshment facilities and are kept separate from production and quality control zones
• These areas include toilets, changing rooms, clothing storage, and washing facilities
• They are equipped with separate air handling systems, entrances, and air locks to prevent contamination of clean areas

Storage Areas

• Storage areas must be designed to provide appropriate conditions based on the requirements of different materials and products
• Separate and clearly labeled storage spaces must be maintained for: starting materials, packaging materials, intermediates, bulk products, finished products, quarantined, released, rejected, returned, and recalled materials
• Access to storage areas should be restricted to authorized personnel only
• Receiving and dispatch areas should be segregated from other storage zones and controlled using measures such as insect catchers, controlled airflow, and compartmentalization

Weighing Areas

• Weighing or dispensing areas must have surfaces that are smooth, impervious, durable, and easy to clean
• All weighing activities and cleaning procedures must be properly documented according to Standard Operating Procedures (SOPs)
• Weighing operations are typically carried out inside a dispensing booth (Class 100 environment) to maintain cleanliness and accuracy

Production Areas

• Separate production facilities should be provided for different categories of products such as antibiotics, penicillin and non-penicillin drugs, hormones, cytotoxic substances, and various dosage forms including injections, solids, liquids, and semisolids
• The design of utilities such as pipework, lighting, ventilation systems, and service points should allow easy access for cleaning and maintenance
• Packaging areas must be specifically designed and organized to prevent mix-ups, contamination, and cross-contamination

Quality Control Areas

• Quality control laboratories must be separate from production areas, with additional separation for microbiological testing sections
• Dedicated air handling systems should be provided to maintain controlled environments
• The design should include sufficient space and proper layout to avoid mix-ups and cross-contamination

Equipment

• Equipment used in pharmaceutical manufacturing must be appropriately located, designed, constructed, adapted, and maintained to suit operational requirements
• The design and placement of equipment should minimize errors and allow effective cleaning and maintenance to prevent contamination, dust accumulation, and negative impacts on product quality
• Measuring instruments such as balances and other machinery must be regularly verified and calibrated according to a predefined schedule
• Equipment must be thoroughly cleaned after use, and cleaning effectiveness should be verified before reuse in subsequent production cycles
• Washing, cleaning, and drying equipment should be carefully selected and used to prevent contamination
• Any defective equipment must be immediately removed or taken out of service to avoid errors in production
• Equipment that comes into direct contact with products should be made of stainless steel grade 316 or 316L, while non-contact parts may use stainless steel grade 304, ensuring materials are non-reactive, non-additive, and non-absorptive
• All equipment must be calibrated at fixed intervals and properly documented
• Equipment and systems should be clearly labeled, including identification of contents and direction of flow, such as in water pipelines and air handling systems

Utilities

• Utilities such as HVAC systems, reverse osmosis (RO) water systems, and compressed air systems are critical for maintaining controlled manufacturing environments
• These systems must be validated regularly, typically on an annual basis, to ensure their effectiveness and consistent performance
• Proper validation and maintenance of utilities help maintain environmental control and overall product quality throughout the manufacturing process

Validation and Qualification

• According to the World Health Organization, validation is defined as the action of proving and documenting that any process, procedure, or method consistently leads to the expected results
• The World Health Organization defines qualification as the action of proving and documenting that premises, systems, and equipment are properly installed and/or operate correctly to produce the expected results
• Qualification must be completed before process validation, as it represents the initial stage of the validation lifecycle
• The qualification process is a logical and systematic approach that begins at the design phase of premises, equipment, and utilities used in both production and quality control
• All systems involved in pharmaceutical quality assurance and quality control must be qualified prior to equipment qualification, including systems such as water purification systems, air-handling systems, and compressed air systems

Stages of Qualification

Design Qualification (DQ)

• Design Qualification is the documented evidence demonstrating that premises, utilities, and equipment are designed in accordance with GMP requirements
• It ensures that the design meets all specifications outlined in the User Requirements Specification (URS) and is capable of fulfilling its intended purpose

Installation Qualification (IQ)

• Installation Qualification is the documented evidence confirming that equipment, premises, and supporting utilities have been properly installed according to approved design specifications
• This stage includes verification of:
• Purchase specifications
• Engineering drawings
• Equipment manuals
• Spare parts lists
• Vendor details
• It ensures that all components are correctly installed and aligned with the design requirements

Operational Qualification (OQ)

• Operational Qualification is the documented verification that systems, subsystems, utilities, or equipment perform as intended across all anticipated operating ranges
• It confirms that operational parameters and controls function according to predefined specifications

Performance Qualification (PQ)

• Performance Qualification is the documented evidence that systems, utilities, or equipment consistently perform and produce reproducible results within defined specifications over an extended period
• It involves collecting and analyzing data over time to demonstrate consistent and reliable performance under routine operating conditions

Quality Risk Management (ICH Q9)

• Quality Risk Management (QRM), as outlined in ICH Q9, is essential for ensuring the development of high-quality pharmaceutical products by systematically addressing risks that may impact product quality, safety, and efficacy
• QRM is defined as a systematic process for the assessment, control, communication, and review of risks throughout the entire product lifecycle
• It helps to:
• Protect patient health by ensuring high-quality medicinal products
• Provide regulatory authorities with confidence in a company’s ability to manage risks
• Optimize and potentially reduce the level of direct regulatory oversight

Risk Assessment

• Risk assessment involves identifying potential risks and evaluating the level of harm associated with them
• A quantitative measure called the Risk Priority Number (RPN) is often used to estimate risk:

RPN=Severity×Probability×Detectability

• Severity refers to the seriousness of the consequences of a hazard
• Probability indicates the likelihood or frequency of occurrence of the hazard
• Detectability measures the ability to identify or detect the hazard before it causes harm
• Risk assessment helps answer key questions:
• What might go wrong?
• What is the probability of occurrence?
• What are the consequences (severity)?

Risk Identification

• Risk identification involves systematically gathering and analyzing information to detect potential hazards
• It focuses on answering the question “What might go wrong?” and identifying all possible consequences associated with those risks

Risk Analysis

• Risk analysis is a qualitative or quantitative process that evaluates the relationship between the likelihood of occurrence and the severity of harm
• In many cases, detectability is also included to provide a more comprehensive estimation of risk

Risk Evaluation

• Risk evaluation involves comparing identified risks against predefined risk criteria
• Subject matter experts assess each risk area by identifying:
• Failure modes
• Associated failure effects
• Scores are assigned for severity, probability, and detectability, and risks are categorized as low, medium, or high based on calculated RPN values

Risk Control

• Risk control aims to reduce risks to an acceptable level and focuses on determining whether risks should be accepted or reduced

Risk Reduction

• When risk levels exceed acceptable limits, mitigation strategies are implemented to reduce risk
• After applying controls, risks must be reassessed to determine:
• Whether the original risk has been eliminated or reduced
• Whether new risks have emerged or existing risks have increased

Risk Acceptance

• If the risk falls within acceptable limits, further risk reduction measures may not be necessary
• However, the decision to accept risk must be justified and documented

Risk Communication

• Effective communication between decision-makers and stakeholders is essential throughout the QRM process
• All risk-related decisions, assessments, and mitigation plans must be well documented

Risk Review

• Risk management outcomes must be continuously reviewed based on new data, knowledge, and experience
• This review may lead to updates in:
• Risk acceptance decisions
• Risk reduction strategies
• Continuous monitoring ensures that risk management remains effective and aligned with current conditions and regulatory expectations

Handling Deviations and CAPA

• Deviation is defined as any departure from approved procedures, processes, or specifications that may impact product quality, safety, or efficacy
• Deviations can occur at any stage of the pharmaceutical product lifecycle, including manufacturing, packaging, labeling, testing, and storage

Deviations are generally classified into two main types

Planned Deviation

• Planned deviations are pre-approved and documented before implementation
• These represent temporary, controlled changes made to meet specific requirements
• Example includes modification of batch size for a certain period due to equipment limitations or shortage of raw materials

Unplanned Deviation

• Unplanned deviations occur unexpectedly and are not approved in advance
• They require immediate investigation to prevent any negative impact on product quality
• Example includes malfunction of equipment, such as a tablet compression machine
• Deviations may also be categorized as minor or major based on their severity and impact
• Effective deviation management is essential to:
• Maintain product quality and consistency
• Ensure regulatory compliance
• Drive continuous improvement
• Prevent recurrence of issues

Steps in Deviation Handling

Deviation Reporting

• All deviations must be reported immediately by personnel to ensure timely tracking and assessment
• Employees should be properly trained to recognize and report deviations

Impact Assessment

• Relevant departments, including QA, Production, QC, and Engineering, must evaluate the impact of the deviation
• Assessment focuses on product quality, data integrity, and regulatory compliance

Root Cause Analysis

• Identifying the root cause of the deviation is critical
• A thorough investigation should be conducted using established tools such as:
• Fishbone (Ishikawa) diagram
• Fault tree analysis
• Pareto chart analysis

Implementation of CAPA

• Based on the root cause, Corrective and Preventive Actions (CAPA) are developed and implemented
• These actions aim to:
• Correct the current issue
• Prevent recurrence of similar deviations

Effectiveness Check

• After CAPA implementation, follow-up activities must be conducted to verify the effectiveness of the actions taken

Documentation

• Proper documentation is essential for traceability and compliance
• Each deviation report should include:
• Unique deviation reference number
• Detailed description of the event
• Impact assessment
• Root cause analysis summary
• CAPA plan
• Approval details and closure date

CAPA (Corrective and Preventive Actions)

• CAPA is a structured system used to address deviations, complaints, audit findings, out-of-specification results, and management review observations
• It is approved by QA and documented to ensure proper closure of deviations
• Corrective Action refers to actions taken to eliminate the root cause of an identified deviation, ensuring it does not recur
• Preventive Action refers to actions taken to eliminate the causes of potential nonconformities before they occur
• CAPA plays a critical role in:
• Ensuring regulatory compliance
• Supporting continuous improvement
• Enhancing accountability and operational efficiency
• Increasing customer satisfaction
• Strengthening overall business practices and quality systems

Conclusion

• Quality is achieved through consistent commitment to high standards in intentions, efforts, execution, and sustained direction throughout pharmaceutical operations
• A product is considered quality, safe, and efficacious when Quality Assurance practices, including Quality Risk Management (QRM) and Product Quality Review (PQR), along with Quality Control (QC) and Good Manufacturing Practice (GMP) norms, are effectively implemented
• Quality Assurance ensures that the guidelines and protocols of GMP, Good Documentation Practice (GDP), and Good Laboratory Practice (GLP) are properly implemented and maintained in coordination with QC and production activities
• A comprehensive quality management system ensures that pharmaceutical products meet regulatory requirements while safeguarding patient health and safety
• Regulatory authorities such as the Food and Drug Administration, European Medicines Agency, Therapeutic Goods Administration, and Health Canada enforce GMP compliance through structured approaches including proper documentation, personnel training, validation processes, and risk management strategies
• In addition to these regulatory bodies, organizations such as the International Organization for Standardization, World Health Organization, and International Council for Harmonisation promote and implement principles of quality management at a global level
• The ALCOA+ principles play a critical role in maintaining GMP compliance by ensuring data integrity, accuracy, and reliability throughout pharmaceutical processes
• These principles enable regulatory authorities to verify that pharmaceutical products are consistently manufactured and tested according to established quality standards
• By effectively integrating all aspects of quality management, the pharmaceutical industry can achieve regulatory compliance, ensure product safety and efficacy, and maintain customer trust and satisfaction

References

• Choudhary, A. (2024, May 2). ALCOA to ALCOA Plus for data integrity: Pharmaceutical guidelines. Pharmaguideline.
• ComplianceQuest. (2023, November 24). QA and QC in the pharmaceutical industry. ComplianceQuest QHSE Solutions. https://www.compliancequest.com/bloglet/quality-assurance-in-pharmaceutical-industry/
• Deviation control in pharmaceuticals. (n.d.). Pharmaguideline. https://www.pharmaguideline.com/2011/01/deviation-control.html
• World Health Organization. (2013). Deviation handling and quality risk management: Guidance for the manufacture of prequalified vaccines for supply to United Nations agencies. https://dcvmn.org/wp-content/uploads/2016/03/who_guidance_deviation_and_risk_mgt_2013.pdf
• Laurent, A. (n.d.). Good manufacturing practice (GMP): Pharma quality assurance guide. Intuition Labs.
• Patel, K. T., & Chotai, N. P. (2011). Documentation and records: Harmonized GMP requirements. Journal of Young Pharmacists, 3(2), 138–150. https://doi.org/10.4103/0975-1483.80303
• Vinod. (2023, September 24). GMP regulations in different countries: A comprehensive overview. GxP Cellators Consultants Ltd. https://www.gxpcellators.com/gmp-regulations-in-different-countries-comprehensive-overview/
• Validation guideline for facility and utility. (2025). Gmpsop. https://www.gmpsop.com/validation-guideline-for-facility-and-utility/
• World Health Organization. (2013). Annex 2: WHO guidelines on quality risk management. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs981-annex2-who-quality-risk-management.pdf
• World Health Organization. (2014). Annex 3: Good manufacturing practices—Guidelines on validation. https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1019-annex3-gmp-validation.pdf